Monster Beverage Down Over 12%, on Pace for Largest Percent Decrease Since March 2018 — Data Talk
Monster Beverage Corporation (MNST) is currently at $44.44, down $6.09 or 12.04%
--Would be lowest close since Oct. 21, 2022, when it closed at $43.80
--On pace for largest percent decrease since March 1, 2018, when it fell 14.44%
--Currently down three of the past four days
--Currently down two consecutive days; down 12.51% over this period
--Worst two day stretch since the two days ending March 12, 2020, when it fell 13.22%
--Down 13.62% month-to-date
--Down 22.85% year-to-date
--Down 26.96% from its all-time closing high of $60.85 on March 13, 2024
--Down 23.50% from 52 weeks ago (Aug. 10, 2023), when it closed at $58.10
--Down 26.96% from its 52-week closing high of $60.85 on March 13, 2024
--Would be a new 52-week closing low
--Traded as low as $43.32; lowest intraday level since Oct. 21, 2022, when it hit $42.80
--Down 14.27% at today's intraday low; largest intraday percent decrease since March 18, 2020, when it fell as much as 15.45%
--Worst performer in the S&P 500 today
--Eighth most active stock in the S&P 500 today
--Worst performer in the Nasdaq 100 today
--Seventh most active stock in the Nasdaq 100 today
All data as of 9:53:48 AM ET
Source: Dow Jones Market Data, FactSet
(END) Dow Jones Newswires
August 08, 2024 10:11 ET (14:11 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Where Top Stock Fund Managers Are Looking Next After the Fed Rate Cut
-
Our Top Pick for Investing in US Renewable Energy
-
Undervalued by 25% and Yielding 5%, This Stock Is a Buy
-
Can AI Predict Future Stock Returns?
-
The Best Energy Stocks to Buy Now
-
10 Undervalued Wide-Moat Stocks
-
Obesity Drugs: Can New Firms Take Market Share From Eli Lilly and Novo Nordisk?
-
New 4-Star Stocks
-
Intel Fair Value Left Unchanged Despite Qualcomm Takeover Talk